Repligen Technologies and Univercells Technologies announced a collaboration integrating Repligen’s MAVEN® Real Time Glucose Control Platform into Univercells' scale-X bioreactors to deliver continuous glucose and lactate monitoring during adherent cell culture processes. This innovation enables up to 720 data points daily without media removal, enhancing process analytical technologies in viral vector and vaccine manufacturing. The partnership aims to optimize cell growth conditions through automated, high-frequency metabolic insights, streamlining scaling and accelerating development of advanced therapies.